The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Open accessAbstract
Recent literature suggested that cells of the microenvironment of tumors could be abnormal as well. To address this hypothesis in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression profiling and phenotypic and functional studies in three groups of individuals: patients with MM, patients with monoclonal gamopathy of undefined significance (MGUS) and healthy age-matched subjects. Gene expression profile independently classified the BMMSCs of these individuals in a normal and in an MM group. MGUS BMMSCs were interspersed between these two groups. Among the 145 distinct genes differentially expressed in MM and normal BMMSCs, 46% may account for a tumor-microenvironment cross-talk. Known soluble factors implicated in MM pathophysiologic features (i.e. IL (interleukin)-6, DKK1) were revealed and new ones were found which are involved in angiogenesis, osteogenic differentiation or tumor growth. In particular, GDF15 was found to induce dose-dependent growth of MOLP-6, a stromal cell-dependent myeloma cell line. Functionally, MM BMMSCs induced an overgrowth of MOLP-6, and their capacity to differentiate into an osteoblastic lineage was impaired. Thus, MM BMMSCs are abnormal and could create a very efficient niche to support the survival and proliferation of the myeloma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secretion of elevated levels of IL-6 by MSC has been detected upon interaction with malignant cells in several epithelial, hematopoietic and mesenchymal cancers (Table 2) [43, 69, 76, 77, 82, 115–119].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, MM-MSCs have different gene profiles from their counterparts in normal MSCs [289, 290].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [289]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationStromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,354
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,330
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Gregory, C. A., Gunn, W., Peister, A., & Prockop, D. J. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.02.002 · Cited by 1,568
Tian, E., Zhan, F., Walker, R. C., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,505
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Cited by
Sorted by citations
Items 201–300 of 331
Plakhova, N., Panagopoulos, V., Cantley, M. D., Trainor, L. J., Hewett, D. R., Clark, K. C., Gardiner, J., Yong, A., Lee, C., Horvath, N., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02621-7 · Cited by 13
Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
Harada, T., & Ozaki, S. (2014) · BioMed Research International · doi:10.1155/2014/965384 · Cited by 13
Higgs, J. T., Lee, J. H., Wang, H., Ramani, V. C., Chanda, D., Hardy, C., Sanderson, R. D., & Ponnazhagan, S. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007310 · Cited by 13
Lemaitre, L., Do Souto Ferreira, L., Joubert, M.-V., Avet-Loiseau, H., Martinet, L., Corre, J., & Couderc, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113854 · Cited by 13
Self-citationKobari, L., Auclair, M., Piau, O., Ferrand, N., Zaoui, M., Delhommeau, F., Fève, B., Sabbah, M., & Garderet, L. (2021) · Leukemia · doi:10.1038/s41375-021-01428-6 · Cited by 14
Hervás-Salcedo, R., & Martín-Antonio, B. (2022) · Cancers · doi:10.3390/cancers14153796 · Cited by 13
Ye, P., Song, X., Lan, J., Wang, X., & Wang, M. (2021) · Medicine · doi:10.1097/md.0000000000023447 · Cited by 13
Analysis of Global Gene Expression Profiles
Kassambara, A., & Moreaux, J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7865-6_11 · Cited by 13
Wang, L., Shi, M., Sung, A. Y., Yin, C. C., Bai, Y., & Chen, M. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150916 · Cited by 14
Misakyan, M. F. F., Wijeratne, E. M. K., Issa, M. E., Xu, Y.-M., Monteillier, A., Gunatilaka, A. A. L., & Cuendet, M. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00446 · Cited by 13
Li, J., Hu, W., Luo, S., Xiong, D., Sun, S., Wang, Y., Bu, X., Liu, J., & Hu, J. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.04.012 · Cited by 11
Biology and Bioinformatics of Myeloma Cell
Abroun, S., Saki, N., Rahim, F., & Asghari, F. (2012) · Laboratory Hematology · doi:10.1532/lh96.11003 · Cited by 11
First steps to define murine amniotic fluid stem cell microenvironment
Bertin, E., Piccoli, M., Franzin, C., Spiro, G., Donà, S., Dedja, A., Schiavi, F., Taschin, E., Bonaldo, P., Braghetta, P., et al. (2016) · Scientific Reports · doi:10.1038/srep37080 · Cited by 11
The therapeutic effect of modified Huangqi Guizhi Wuwu Tang for multiple myeloma
Tian, M., & Huang, H. (2017) · Medicine · doi:10.1097/md.0000000000009074 · Cited by 11
Modification of the bone marrow MSC population in a xenograft model of early multiple myeloma
Berlier, J. L., Rethnam, M., Majeed, A., & Suda, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.178 · Cited by 11
Banaszkiewicz, M., Małyszko, J., Batko, K., Koc‐Żórawska, E., Żórawski, M., Dumnicka, P., Jurczyszyn, A. J., Woziwodzka, K., Tisończyk, J., Krzanowski, M., et al. (2020) · Mediators of Inflammation · doi:10.1155/2020/5657864 · Cited by 11
Myeloma–Bone Interaction: A Vicious Cycle via TAK1–PIM2 Signaling
Harada, T., Hiasa, M., Teramachi, J., & Abe, M. (2021) · Cancers · doi:10.3390/cancers13174441 · Cited by 12
Choi, D. S., Stark, D. J., Raphael, R. M., Wen, J., Su, J., Zhou, X., Chang, C.-C., & Zu, Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.29145 · Cited by 11
Schoenhals, M. J., Frecha, C. A., Bruyer, A., Caraux, A., Veyrune, J., Jourdan, M., Moreaux, J., Cosset, F., Verhoeyen, E., & Klein, B. (2012) · Leukemia · doi:10.1038/leu.2012.36 · Cited by 11
Self-citationLemaitre, L., Hamaïdia, M., Descamps, J.-G., Souto, L. D., Joubert, M.-V., Gadelorge, M., Avet‐Loiseau, H., Justo, A., Reina, N., Deschaseaux, F., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003704 · Cited by 10
Self-citationLokhorst, H. M., van der Holt, B., Cornelissen, J. J., Kersten, M. J., van Oers, M. H. J., Raymakers, R. A. P., Minnema, M. C., Zweegman, S., Bos, G. M. J., Schaap, N. P., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.128728 · Cited by 11
Impact of connexin 43 coupling on survival and migration of multiple myeloma cells
Zhang, Y., Wang, Z., Zhang, L., Zhou, D., Sun, Y., Wang, P., Ju, S., Chen, P., Li, J., & Fu, J. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.71065 · Cited by 10
DLL4 restores damaged liver by enhancing hBMSC differentiation into cholangiocytes
Sun, S., Yuan, L., An, Z., Shi, D., Xin, J., Jiang, J., Ren, K., Chen, J., Guo, B., Zhou, X., et al. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.101900 · Cited by 10
Lin, H., Hwang, S., Wu, S., Hsu, L., Liao, Y., Sheen, Y., Chuang, W., & Huang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094395 · Cited by 11
Haga, C. L., Boregowda, S. V., Booker, C. N., Krishnappa, V., Strivelli, J., Cappelli, E., & Phinney, D. G. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.11.003 · Cited by 9
Plano, F., Corsale, A. M., Gigliotta, E., Camarda, G. M., Vullo, C., Simone, M. D., Azgomi, M. S., Speciale, M., Carlisi, M., Caccamo, N., et al. (2023) · Hematology Reports · doi:10.3390/hematolrep15010004 · Cited by 11
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease
Johansen, M., Levring, M. B., Stokbro, K., Diaz‐delCastillo, M., Khan, A. A., Wickstrøm, L. A., Gundesen, M. T., Kristensen, I. B., Nyvold, C. G., Andersen, M. Ø., et al. (2023) · Cancers · doi:10.3390/cancers15235585 · Cited by 12
The role of CCN family genes in haematological malignancies
Wells, J. E., Howlett, M., Cheung, L. C., & Kees, U. R. (2015) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-015-0296-4 · Cited by 9
Allogeneic Versus Autologous Mesenchymal Stromal Cells and Donor-to-Donor Variability
Qayed, M. D., Copland, I. B., & Galipeau, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802826-1.00004-0 · Cited by 9
Factors affecting the role of canonical Wnt inhibitor Dickkopf-1 in cancer progression
Doucet, D., Brubaker, C., Turner, D., & Gregory, C. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1114822 · Cited by 8
Yu, L., Zheng, C., Zhang, W., Liu, X., Zhou, Z., Wang, Z., Hua, H., Song, Z., Zhang, X., Liu, S., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03308-2 · Cited by 8
Pevsner‐Fischer, M., Levin, S., Hammer-Topaz, T., Cohen, Y., Mor, F., Wagemaker, G., Nagler, A., Cohen, I. R., & Zipori, D. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9310-2 · Cited by 8
Litvinova, L. S., Геннадьевна, Х. О., Shupletsova, V. V., Yurova, K. A., Malashchenko, V. V., Shunkin, E. O., Ivanov, P. A., Геннадьевна, К. Е., Chebodaeva, V. V., Porokhova, E. D., et al. (2020) · Materials · doi:10.3390/ma13194307 · Cited by 8
Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells
Espagnolle, N., Hébraud, B., Descamps, J.-G., Gadelorge, M., Joubert, M.-V., Souto, L. D., Roussel, M., Huynh, A., Sensebé, L., Casteilla, L., et al. (2020) · Stem Cells International · doi:10.1155/2020/4173578 · Cited by 8
Self-citationMolecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma
Iannozzi, N. T., Marchica, V., Toscani, D., Burroughs-Garcìa, J., Giuliani, N., & Storti, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415448 · Cited by 7
Giuliani, N., Lisignoli, G., Novara, F., Storti, P., Zaffaroni, N., Villa, R., Sammarelli, G., Agnelli, L., Todoerti, K., Bernardo, M. E., et al. (2010) · Leukemia · doi:10.1038/leu.2010.96 · Cited by 7
Martínez‐Jaramillo, G., Vela‐Ojeda, J., Flores-Guzmán, P., & Mayani, H. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.06.014 · Cited by 7
Hematopoietic and microenvironment alterations in bone marrow from patients with multiple myeloma
Mayani, H. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.11.012 · Cited by 7
Bong, I. P. N., Ng, C. C., Othman, N., & Esa, E. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01272-7 · Cited by 6
Vilchis-Ordóñez, A., Dorantes-Acosta, E. M., Vadillo, E., López-Martı́nez, B., & Pelayo, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-05798-9_9 · Cited by 6
Nadav, L., Kalchenko, V., Barak, M. M., Naparstek, E., Geiger, B., & Katz, B.-Z. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.05.009 · Cited by 6
Yuan, M., Chen, J., & Zeng, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5879 · Cited by 5
Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma
Fernando, R. C., de Carvalho, F., Leme, A. F. P., & Colleoni, G. W. B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.563384 · Cited by 5
Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells
Deng, M., Yuan, H., Peng, H., Liu, S., Xiao, X., Wang, Z., Zhang, G., & Xiao, H. (2022) · Stem Cells International · doi:10.1155/2022/4855517 · Cited by 5
The role of the bone marrow microenvironment in the pathogenesis of multiple myeloma
Jurczyszyn, A. J., Gdula‐Argasińska, J., Kosmaczewska, A., & Skotnicki, A. B. (2015) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1150216 · Cited by 5
Cell-based assays for IGF-I bioactivity measurement: overview, limitations and current trends
Ramadhin, C., Pillay, B., & Olaniran, A. O. (2014) · Growth Factors · doi:10.3109/08977194.2014.939806 · Cited by 5
Role of MSCs in Antitumor Drug Resistance
Naour, A. L., & Couderc, B. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803102-5.00013-6 · Cited by 6
Su, C., Tao, D., Ren, L., Guo, S., Zhou, W., Wu, H., & Jiang, H. (2020) · Tissue and Cell · doi:10.1016/j.tice.2020.101406 · Cited by 5
Cytotherapies in multiple myeloma: a complementary approach to current treatments?
Ciavarella, S., Caselli, A., Savonarola, A., Tamma, A. V., Tucci, M., & Silvestris, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.796357 · Cited by 5
Calkoen, F., Vervat, C., Eising, E., Vijfhuizen, L. S., Hoen, P. A. C. ’., van den Heuvel‐Eibrink, M. M., Egeler, R. M., van Tol, M. J. D., & Ball, L. M. (2015) · Haematologica · doi:10.3324/haematol.2015.126938 · Cited by 5
Abdi, J., & Nasr, P. (2025) · Frontiers in Hematology · doi:10.3389/frhem.2025.1435193 · Cited by 4
Aristizábal, J. A., Chandía, M., del Cañizo, M. C., & Sanchez-Guijo, F. M. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014000500008 · Cited by 4
Hematopoietic Stem Cell Niche: Role in Normal and Malignant Hematopoiesis
Sergio, P., Levy, D., Jorge, M. L., & Pereir, J. (2013) · InTech eBooks · doi:10.5772/55508 · Cited by 4
Yoon, J. S., Kim, E. S., HWANG, D. W., Choi, J., Kim, B. K., PARK, B. B., Choi, J.-H., & LEE, Y. Y. (2010) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2010.01285.x · Cited by 4
Terpos, E., & Gavriatopoulou, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65375-8 · Cited by 4
Yellow adipocytes comprise a new adipocyte sub-type present in human bone marrowPreprint
Attané, C., Estève, D., Chaoui, K., Iacovoni, J. S., Corre, J., Moutahir, M., Valet, P., Burlet‐Schiltz, O., Reina, N., & Muller, C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/641886 · Cited by 4
Self-citationHaskell, A. W., Pan, S., Reese, R., Powers, A., Lopez, M. G., Lomeli, S., Story, C., Benton, J., Blazier, J. C., Kaunas, R. R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84037-4 · Cited by 3
Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease
Wang, J., Baardemans, T., Simoes, R. D. M., Noort, W. A., Ruiter, R. W. J., Prins, H., Veen, S. E. V. H.-V., Yuan, H., de Bruijn, J. D., Martens, A. C., et al. (2025) · Biomolecules · doi:10.3390/biom15121747 · Cited by 3
Shipounova, I. N. (2014) · Journal of Leukemia · doi:10.4172/2329-6917.1000153 · Cited by 3
Microenvironment for myeloma growth and drug resistance
Abe, M. (2013) · Cited by 3
Kim, S. Y., Im, K., Park, S. N., Oh, B., Kim, J., Hwang, S. M., Kim, M., Yoon, S.-S., & Lee, D. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.86 · Cited by 3
Kalantari, N., Abroun, S., Soleimani, M., Kaviani, S., Azad, M., Eskandari, F., & Habibi, H. (2016) · PubMed Central · doi:10.22074/cellj.2016.4559 · Cited by 3
Ichii, M., & Hosen, N. (2020) · Cancers · doi:10.3390/cancers13010025 · Cited by 4
Pan, J., Jiang, Y., Li, C., Jin, T., Yu, K., & Jin, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.898236 · Cited by 3
Spotlight review series on multiple myeloma
Rajkumar, S. V., & Killmann, N. M.-B. (2009) · Leukemia · doi:10.1038/leu.2009.243 · Cited by 3
Ghoshal, D., Petersen, I., Ringquist, R., Kramer, L., Bhatia, E., Hu, T., Richard, A., Park, R., Corbin, J., Agarwal, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.08.588601 · Cited by 4
Mesenchymal stem cells: paving the way for myeloma onset?
Gullà, A., & Fulciniti, M. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012705 · Cited by 2
Paula‐Manuela, R. Z., Meyer-Herrera, J. E., Ruiz-Aparicio, P. F., & Vernot, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098157 · Cited by 2
Phenotypic and functional alterations of bone marrow MSCs exposed to multiple myeloma cells
Kim, H. J., Eom, S. Y., Hwang, S., Kim, H., Won, J., Chung, S. H., & Yahng, S. (2023) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00415-5 · Cited by 2
Proteasome Inhibitors and the Wnt Signaling Pathway in Myeloma Bone Disease
Edwards, C. M., & Mundy, G. R. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-554-5_12 · Cited by 2
Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in Multiple Myeloma
Mera Azaín, C. A., Vargas Pasquel, J. L., Quijano Gómez, S. M., & Rodríguez-Pardo, V. M. (2024) · Hematology Reports · doi:10.3390/hematolrep16040070 · Cited by 1
“(Figure 1) [25,26].”
Meyer, T. J., Hackenberg, S., Herrmann, M., Gehrke, T. E., Steber, M., Hagen, R., Kleinsasser, N. H., & Scherzad, A. (2022) · Oncology Letters · doi:10.3892/ol.2022.13570 · Cited by 1
To treat or not to treat: a state-of-the-art overview of smoldering multiple myeloma
Garg, A., & Devarakonda, S. S. (2026) · Frontiers in Hematology · doi:10.3389/frhem.2025.1706219 · Cited by 1
Exploiting cellular senescence in hematologic malignancies
Jiang, P., Yang, G., Li, J., Tian, X., Yang, X., Yang, S., Wei, J., Zhang, X., & Liu, J. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102729 · Cited by 1
Bone Marrow Microenvironment in the Pathogenesis of AML
Blau, O. (2011) · InTech eBooks · doi:10.5772/25889 · Cited by 1
Ness, B. V. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_31 · Cited by 1
Podar, K., & Anderson, K. C. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s2889 · Cited by 1
The Role of Mesenchymal Cells in Cancer: Contribution to Tumor Stroma and Tumorigenic Capacity
Shoshani, O., & Zipori, D. (2010) · Springer eBooks · doi:10.1007/978-90-481-9531-2_5 · Cited by 1
Kosmaczewska, A., Masternak, A., & Kosciow, K. (2013) · OA Immunology · doi:10.13172/2052-9295-1-1-1018 · Cited by 1
Mesenchymal Stromal Cells and Tumor Angiogenesis
Hung, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803102-5.00012-4 · Cited by 1
Molecular Aberrations in Bone Marrow Stromal Cells in Multiple Myeloma
Blau, O., Berenstein, R., Wächter, M., Nogai, A., Künel, A., Bayanova, M., & Blau, I. W. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77179 · Cited by 1
Lasaviciute, G., Höbinger, A., Ujvári, D., Salamon, D., Yusuf, A., Sundin, M., Sverremark‐Ekström, E., Chikhi, R., Nilsson, A., & Saghafian‐Hedengren, S. (2021) · Hemato · doi:10.3390/hemato2010009 · Cited by 1
Valsecchi, C., Croce, S., Maltese, A., Montagna, L., Lenta, E., Nevone, A., Girelli, M., Milani, P., Bosoni, T., Massa, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111523 · Cited by 1
Avet‐Loiseau, H., & Corre, J. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6_1 · Cited by 1
Self-citationBone Marrow Adipose Tissue: Impacts on Bone Marrow Stem Cell Niche and Hematopoietic System
Trivanović, D. I., & Drvenica, I. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00096-2 · Cited by 1
Agostini, F., Vicinanza, C., Lombardi, E., Ros, F. D., Marangon, M., Massarut, S., Mazzucato, M., & Durante, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1404228 · Cited by 1
The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes
Giuliani, N., Costa, F., & Marchica, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-63662-3_3 · Cited by 1
Gregory, C. A. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701625115 · Cited by 1
Corre, J. (2013) · Acta Haematologica · doi:10.1159/000355129 · Cited by 1
Self-citationGiuliani, N., & Rizzoli, V. (2009) · Hematology Meeting Reports · doi:10.4081/hmr.v3i3.556
Role of Osteoblast in Myeloma Pathology
Vallet, S., & Raje, N. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_11
Growth Factors in Multiple Myeloma
Moreaux, J., Bret, C., Mahtouk, K., Sprynski, A. C., Hose, D., & Klein, B. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_4
Self-citationChung, T., & Chng, W. J. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.18
Cytokine Pathways in Myeloma Growth and Survival
Sprynski, A. C., Hose, D., Moreaux, J., Reme, T. X., Jourdan, M., Bourin, P., Corre, J., Barlogie, B., Shaughnessy, J. D., Rossi, J. F., et al. (2009) · Clinical Lymphoma & Myeloma · doi:10.1016/s1557-9190(11)70808-3
Self-citationNOTCH PRODUCES A DEREGULATION OF CXCR4/SDF-1A CHEMOKINE SIGNALING IN MULTIPLE MYELOMA CELLS
Apicella, L. (2013) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/apicella-luana_phd2013-02-07
Mechanisms Involved in Osteoblast Suppression in Multiple Myeloma
Giuliani, N. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-554-5_13
The role of human mesenchymal stem cells in repair of bone
Gunn, W. (2009) · ProQuest Demo Repository
Colombo, M. (2014) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/colombo-michela_phd2014-01-27
The myeloma bone marrow environment and survival signaling
Khwaja, A., Quinn, J., & Yong, K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511862465.006
Cytogenetic changes of mesenchymal stem cells in the neoplastic bone marrow niche in leukemia
Ferdowsi, S., Azizidoost, S., Nasim, G., & Saki, N. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1408-0
Metadata
- Authors
- Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., & Bourin, P.
- Affiliations
- Établissement Français du Sang (FR)
- Inserm (FR)
- Hôpital Purpan (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Bourin, P
- Venue
- Leukemia
- Published
- 2007-03-08
- Volume
- 21
- Issue
- 5
- Pages
- 1079-1088
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC2346535
- OpenAlex
- W2048064990
- Cited by
- 328
- References
- 62
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 13 · 2023: 11 · 2022: 12 · 2021: 20 · 2020: 18 · 2019: 10 · 2018: 18 · 2017: 21 · 2016: 21 · 2015: 18 · 2014: 23 · 2013: 25 · 2012: 25
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple myeloma, bone marrow mesenchymal stem cells, tumor microenvironment, monoclonal gammopathy of undetermined significance, gene expression profiling, interleukin-6, DKK1, GDF15, angiogenesis, osteogenic differentiation
- MeSH terms
- Adult, Aged, Bone Marrow Cells, Cell Differentiation, Female, Hematopoiesis, Humans, Male, Middle Aged, Multiple Myeloma, Osteoblasts, Cytokines, Gene Expression Profiling, Cell Proliferation, Growth Differentiation Factor 15, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
